|
Powered by Cell Signaling Technology |
Site Information |
---|
ANMERIMkAQALrDN SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 8107214 |
Available spectra: 2 CST |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
References | |
---|---|
Olsen JB, et al. (2016) Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics. Mol Cell Proteomics 15, 892-905
26750096 Curated Info |
|
Wu Z, et al. (2015) A chemical proteomics approach for global analysis of lysine monomethylome profiling. Mol Cell Proteomics 14, 329-39
25505155 Curated Info |
|
Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87
24129315 Curated Info |
|
Bremang M, et al. (2013) Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. Mol Biosyst 9, 2231-47
23748837 Curated Info |
|
Rikova K (2013) CST Curation Set: 18853; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Rikova K (2013) CST Curation Set: 18852; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Cao XJ, Arnaudo AM, Garcia BA (2013) Large-scale global identification of protein lysine methylation in vivo. Epigenetics 8, 477-85
23644510 Curated Info |
|
Rikova K (2012) CST Curation Set: 16504; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Rikova K (2012) CST Curation Set: 16501; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Rikova K (2012) CST Curation Set: 16502; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Rikova K (2012) CST Curation Set: 16503; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Mulhern D (2012) CST Curation Set: 14368; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Tucker M (2010) CST Curation Set: 9906; Year: 2010; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Tucker M (2010) CST Curation Set: 9897; Year: 2010; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Tucker M (2010) CST Curation Set: 9911; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Tucker M (2010) CST Curation Set: 9898; Year: 2010; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Tucker M (2010) CST Curation Set: 9905; Year: 2010; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Tucker M (2010) CST Curation Set: 9904; Year: 2010; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Tucker M (2010) CST Curation Set: 9909; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Tucker M (2010) CST Curation Set: 9901; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Tucker M (2010) CST Curation Set: 9899; Year: 2010; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Tucker M (2010) CST Curation Set: 9900; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Possemato A (2009) CST Curation Set: 8360; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |
|
Possemato A (2009) CST Curation Set: 8353; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K
Curated Info |